Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson’s disease-A computational study

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson's disease-A computational study September 15, 2023 Aging Med (Milton). 2022 Dec 20;6(3):272-280. doi: 10.1002/agm2.12235. eCollection 2023 Sep.ABSTRACTOBJECTIVE: This study aims to find the most promising Ganoderma lucidium targeting LRRK2 involved in PD.METHODS: First ADMET analysis was performed for five compounds followed by molecular docking of each compound. Then, we perform molecular dynamics simulation of all five compounds and finally MMGBSA of all five compounds.RESULTS: Based on…
• Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson's disease-A computational study September 15, 2023 Aging Med (Milton). 2022 Dec 20;6(3):272-280. doi: 10.1002/agm2.12235. eCollection 2023 Sep.ABSTRACTOBJECTIVE: This study aims to find the most promising Ganoderma lucidium targeting LRRK2 involved in PD.METHODS: First ADMET analysis was performed for five compounds followed by molecular docking of each compound. Then, we perform molecular dynamics simulation of all five compounds and finally MMGBSA of all five compounds.RESULTS: Based on…
• Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson's disease-A computational study September 15, 2023 Aging Med (Milton). 2022 Dec 20;6(3):272-280. doi: 10.1002/agm2.12235. eCollection 2023 Sep.ABSTRACTOBJECTIVE: This study aims to find the most promising Ganoderma lucidium targeting LRRK2 involved in PD.METHODS: First ADMET analysis was performed for five compounds followed by molecular docking of each compound. Then, we perform molecular dynamics simulation of all five compounds and finally MMGBSA of all five compounds.RESULTS: Based on…
• Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson's disease-A computational study September 15, 2023 Aging Med (Milton). 2022 Dec 20;6(3):272-280. doi: 10.1002/agm2.12235. eCollection 2023 Sep.ABSTRACTOBJECTIVE: This study aims to find the most promising Ganoderma lucidium targeting LRRK2 involved in PD.METHODS: First ADMET analysis was performed for five compounds followed by molecular docking of each compound. Then, we perform molecular dynamics simulation of all five compounds and finally MMGBSA of all five compounds.RESULTS: Based on…
• Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson's disease-A computational study September 15, 2023 Aging Med (Milton). 2022 Dec 20;6(3):272-280. doi: 10.1002/agm2.12235. eCollection 2023 Sep.ABSTRACTOBJECTIVE: This study aims to find the most promising Ganoderma lucidium targeting LRRK2 involved in PD.METHODS: First ADMET analysis was performed for five compounds followed by molecular docking of each compound. Then, we perform molecular dynamics simulation of all five compounds and finally MMGBSA of all five compounds.RESULTS: Based on…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• The Llama-nation of LRRK2 April 8, 2022 # # # # Antibodies are tiny y-shaped markers used by the immune system to label foreign agents within the body. Once bound to something, antibodies can alert immune cells to come and remove the object. Antibodies can also inhibit the object from doing anything nasty, like infecting or damaging a cell. Between species, different types of antibodies have been…
• Denali’s Phase I results May 27, 2021 # # # # Leucine-rich repeat kinase 2 (or LRRK2) is a large, multi function protein that is associated with Parkinson’s. People with genetic variations in the region of DNA that provides the instructions for making LRRK2 protein have a higher risk of developing the condition. In many cases of Parkinson’s, LRRK2 can become hyperactive. Researchers and biotech companies have…
• The luminance of a lighthouse January 24, 2022 # # # # LRRK2 inhibition represents one of several biological approaches to slowing the progression of Parkinson’s that is currently being clinically tested. Leading the charge in the development of LRRK2 inhibitors is a biotech company called Denali Therapeutics (in partnership with Biogen). Recently, the company provided news on the immediate future clinical development plans for their lead molecule…
• Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
• Monthly Research Review – February 2022 February 28, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Monthly Research Review – July 2021 July 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Monthly Research Review – September 2021 September 30, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2021. The post is divided into 10 parts based on the type of research: Top 4 pieces of Parkinson’s news Articles of general interest Basic biology…
• Unmasking LRRK2 and GBA May 22, 2021 # # # # Connecting genetics and biology is complicated. Researchers around the world have struggled to determine what each functional region of DNA is doing individually, let alone in combination with other regions. And sometimes when the output of combinations is examined, the results can be unexpected. Recently, researchers looked at the consequences of having a particular combination of…
• The Aging Immune System and Parkinson’s October 10, 2022 “Come grow old with me. The best is yet to be.” William Wordsworth “As long as I am breathing, in my eyes, I am just beginning.” Criss Jami Introduction: Recently, an exciting and in-depth review article about inflammation and the immune system and their dysfunction in the pathway of Parkinson’s was published. The citation for this paper is as follows:…
• Monthly Research Review – July 2022 July 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Getting a handle on Miro1 December 3, 2021 # # # # Novel therapeutic interventions are being proposed for Parkinson’s on a regular basis, with compelling data supporting their future development. The case is strengthened when a measure of target engagement is also involved – providing not only a potential therapy but also a biomarker as well. Recently, a biotech company called AcureX Therapeutics has been presenting just…
• Monthly Research Review – August 2021 August 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during August 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…